Hyperfine, Inc. (HYPR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 27% revenue increase and record gross margins, driven by new product launches. Although the company remains unprofitable, reduced cash burn and a robust pipeline suggest positive momentum. The Q&A reveals cautious optimism, with management focusing on near-term growth and international expansion challenges. The lack of 2026 guidance is a minor concern but is offset by positive indicators like increased sales and cash optimization, leading to a positive sentiment.
Key Financial Performance
Revenue $3.4 million, up 27% sequentially. The increase was driven by the launch of the next-generation Swoop system and Opti AI software, as well as a strong mix of next-generation system sales.
Gross Margin 53.8%, a record and representing a 450 basis point increase sequentially. This was driven by the increased average selling price of the next-generation Swoop system.
R&D Expenses $4.0 million, a sequential quarterly decrease from $4.5 million in the second quarter of 2025. The decrease was attributed to the benefits of the reorganization completed in the first quarter as the company transitions to a commercial growth stage organization.
Sales, General and Administrative Expenses $6.7 million, compared to $6.4 million in the second quarter of 2025. The increase reflects ongoing commercial launch activities and associated growth trajectory.
Net Loss $11.0 million, equating to a net loss of $0.14 per share, compared to a net loss of $9.2 million or $0.12 per share in the prior sequential quarter. The increase in net loss included a noncash change in fair value of warrant liabilities of $2.3 million.
Net Cash Burn (excluding financing) $5.9 million, down 27% sequentially from the prior quarter. The reduction reflects spending discipline and optimization of operating leverage.
Cash and Cash Equivalents $21.6 million as of September 30, 2025. This does not include the $18.4 million in net proceeds raised from October equity financing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of next-generation Swoop system and Opti AI software: The company introduced its next-generation Swoop system and Opti AI software, which have received positive user feedback and are ready for mainstream adoption. The new system offers improved image quality, user-centric design, and accessibility for diverse patient populations.
Proprietary hardware and software updates: The new scanner hardware allows for software-driven image quality improvements, with updates planned at a cadence of 1-2 releases per year. The first upgrade to Opti AI software is scheduled for Q1 2026.
U.S. hospital market expansion: The next-generation Swoop system has been placed in various hospital settings, including adult and pediatric critical care and emergency departments. Hospitals are showing strong interest due to the system's economic value and clinical utility.
Neurology office market entry: The company launched the Swoop system into neurology offices, targeting a large market where only 10% of private practices currently have MRI equipment. Clinical studies are underway to validate its utility in this setting.
International market growth: Received CE Mark and U.K. CA Mark approvals for Opti AI software, with plans to launch in 10 European languages by year-end. Expansion into Europe, Canada, and India is anticipated by the end of 2026.
Revenue growth and financial performance: Q3 2025 revenue was $3.4 million, up 27% sequentially, with a record gross margin of 53.8%. The company expects Q4 revenue of $5-6 million, representing significant growth.
Cash burn reduction: Net cash burn decreased by 27% sequentially in Q3 2025, with a strong cash position extending the runway into the second half of 2027.
Diversified revenue streams: The company is focusing on three verticals: hospitals, neurology offices, and international markets, to drive growth and financial performance.
Clinical studies and evidence generation: Ongoing studies like PRIME and PRISM PMR aim to expand use cases and validate the clinical utility of the Swoop system in various settings.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is awaiting regulatory approval for its next-generation system in India and plans to launch in Europe and Canada by the end of 2026. Delays or failures in obtaining these approvals could hinder international expansion.
Cash Burn and Financial Sustainability: Despite reducing cash burn by 27% sequentially, the company still reported a net loss of $11 million in Q3 2025. Sustained losses and high cash burn could impact long-term financial sustainability.
Market Adoption and Competition: While the next-generation system has received positive feedback, its adoption depends on convincing hospitals, neurology offices, and international markets of its value. Competitive pressures from established MRI providers could pose challenges.
Operational Execution: The company is transitioning from a first-generation product to a next-generation system. Any missteps in execution, such as delays in product rollouts or supply chain disruptions, could impact growth.
Economic Value Proposition: The company emphasizes the economic benefits of its system, such as reducing costs and accelerating patient progress. However, failure to demonstrate these benefits convincingly to potential buyers could slow adoption.
International Expansion: The company is focusing on international markets, including Europe, Canada, and India. Challenges in localization, regulatory compliance, and market penetration could impact growth.
Clinical Validation: Ongoing clinical studies are critical for proving the system's utility. Delays or negative outcomes in these studies could affect market confidence and adoption.
Revenue Growth and Profitability: The company expects significant revenue growth but remains unprofitable. Achieving profitability while scaling operations is a key challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue for the fourth quarter of 2025 is expected to be approximately $5 million to $6 million, representing sequential and year-over-year quarterly growth of 60% and 137%, respectively. Full-year 2025 revenue is projected to be approximately $13 million to $14 million.
Gross Margin Projections: Gross margins for the full year 2025 are expected to range between 49% to 51%, with gross margins exceeding 50% going forward due to higher volumes and average selling prices.
Cash Burn and Financial Position: Total cash burn for the full year 2025 is projected to be in the range of $29 million to $31 million, a 22% decline year-over-year. The company expects its cash runway to last into the second half of 2027.
Product Development and Upgrades: The first upgrade to the OPTI AI software is planned for release in the first quarter of 2026, with subsequent updates expected at a cadence of 1 to 2 releases per year.
Market Expansion: The next-generation Swoop system is expected to be available in Europe and Canada by the end of 2026. Regulatory approval in India is anticipated before the end of 2025. The company plans to launch OPTI AI in 10 European languages by the end of 2025.
Clinical Studies and Data: The Neuro PMR study has completed enrollment, with data expected in early 2026. The PRIME study and PRISM PMR study are ongoing, with over 75 and 20 patients enrolled, respectively.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details about the composition of the backlog and what supports the $5 million to $6 million fourth quarter guidance?
A:The backlog is managed across three pipelines: U.S. hospital deals, U.S. office deals, and international business. The pipeline is robust and growing significantly, with more deals involving multiple units and deeper penetration into IDNs. The fourth quarter guidance is based on this pipeline growth and diversification across geographies and verticals. The second quarter of the launch for next-generation technology in hospitals and offices is also contributing to the guidance.
Q:Can you provide any directional comments on 2026 growth?
A:Management declined to provide specific guidance for 2026, emphasizing that they are focused on the near-term performance in Q4 2025 and the early stages of the launch. They noted that 2026 growth will depend on the three pipelines and the time required for hospital deals to materialize.
Q:What is the timeline and trajectory for market penetration in urology offices, and when can we expect a ramp-up of orders?
A:The pipeline for urology offices is active, with segmentation between solo practitioners and multi-practitioner practices. The adoption depends on practice size and scan volume. Strategies include offering flexible pricing for smaller offices and targeting larger practices with next-generation technology. Partnerships and participation in relevant meetings are also part of the strategy. However, no specific penetration metrics were provided.
Q:Does international expansion take similar or longer time compared to the U.S., and what are the major bottlenecks?
A:International expansion focuses on hospitals and involves procurement and tendering processes, which are generally slower than U.S. office decisions. A significant development is the French referencing process, which expedites transactions in France. The launch of new image quality software in 10 local languages in Q4 is expected to support international growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance or directional comments for 2026, citing the early stages of the launch and the need to focus on near-term performance. They used vague language and deferred detailed commentary until early 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI software
Brett
MRI scanner
MRI technology
OPTI AI
Opti AI
Optive AI
PMR
Swoop system
Swoops system
activation
addition
adoption swoop
capital position
community
feedback
generation Swoop
generation swoop
generation system
health system
month
placement
potential
proceeds
radiology
record selling
room
set
sheet cash
size
swoop system
system Opti
system Optive
system deal
system hospital
technology mainstream
today Inc
value proposition
year
HYPR Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call indicated strong financial performance with an 83% revenue increase and improved gross margins. The strategic plan outlines international expansion and product development, while the Q&A section highlighted positive reception of the Swoop system and no impact from helium shortages. Despite a net loss, reduced R&D expenses and cash burn demonstrate financial discipline. The guidance aligns with growth initiatives, and the company's innovative approach and market potential suggest a positive stock price movement in the near term.
AutoCanada Inc. (ACQ:CA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed significant challenges, including declining revenue and gross profit, operational disruptions, and inventory management issues. The Q&A highlighted ongoing pressures on used vehicle gross profit and the need for a strategic reset. Although there is potential for improvement in the long term, the immediate outlook remains negative due to these persistent challenges and market underperformance.
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings report shows strong financial performance with significant revenue and gross profit growth, reduced net loss, and improved cash burn. The optimistic guidance for 2026, strong pipeline, and increased pricing for Model 2 suggest positive future prospects. Despite some management avoidance in addressing specific deal sizes, the overall sentiment is positive, supported by the transition to broader clinical utility and strategic market expansion.
HYPR Slides
HYPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
